Previous Page  14 / 49 Next Page
Show Menu
Previous Page 14 / 49 Next Page
Page Background


There has been a strong commitment by the Members of the European Parliament to

support the paediatric haematology-oncology agenda, for instance via their endorsement

of the SIOPE-ENCCA-ICCCPO Manifesto for Paediatric Oncology.


Advocacy groups of parents, patients and survivors advocates are increasingly well

organized in Europe (through Childhood Cancer International (CCI), formerly ICCCPO)

and are strongly committed and equal partners in the European care and research agenda.


Charities in several countries are committed to support and finance research programmes

on cancer in children and teenagers.


There is a possibility that due to factors such as a high cure rates, decision-making leaders

at the European and national levels might consider that paediatric cancer is not a priority,

supposing that all efforts should be concentrated only on cancer prevention in adults

and on transforming cancer into a controlled chronic disease in the ageing population.


The global economic crisis hindered the capacity of several EU Member States to improve

their healthcare system to deliver standard treatments for young people with cancer.


There is limited access to some essential medicines, due to drug shortages and to the high

price of new medicines.


Issues around the lack of collection of data in patients with diseases that have a good

prognosis under standard treatment mean that the quality of care and, eventually, the

probability of cure will be decreased.


Wide-ranging EU regulatory initiatives might negatively impact the implementation of the

goals of the paediatric haematology-oncology community, for example the EU General

Data Protection Regulation (2012/0011(COD)) under discussion at the time of publication

could impact on research and trials.




From AIEOP. Credit Attilio Rossetti photographer, Italy

“The needs of children with cancer have not been

high on the political radar” (Richard Sullivan, UK)